Oric Pharmaceuticals (ORIC) Total Non-Current Liabilities (2020 - 2026)

Oric Pharmaceuticals' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $17.8 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 0.87% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (up 0.87% YoY) and the FY2025 annual result came in at $20.4 million, down 17.83% from the prior year.
• Total Non-Current Liabilities was $17.8 million for Q1 2026 at Oric Pharmaceuticals, down from $20.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $24.8 million in Q4 2024 and bottomed at $11.8 million in Q1 2022.
• A 5-year average of $17.4 million and a median of $17.8 million in 2026 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 53.95% — and 2025, when it fell 17.83%.
• Oric Pharmaceuticals' Total Non-Current Liabilities stood at $15.4 million in 2022, then jumped by 32.95% to $20.5 million in 2023, then increased by 21.45% to $24.8 million in 2024, then decreased by 17.83% to $20.4 million in 2025, then declined by 12.96% to $17.8 million in 2026.
• Business Quant data shows ORIC's Total Non-Current Liabilities at $17.8 million in Q1 2026, $20.4 million in Q4 2025, and $20.2 million in Q3 2025.